{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:41:06Z","timestamp":1794850866809,"version":"4.9.1"},"reference-count":141,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM121334"],"award-info":[{"award-number":["P20GM121334"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R21DK113500"],"award-info":[{"award-number":["R21DK113500"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["F30DK127527"],"award-info":[{"award-number":["F30DK127527"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS is characterized by androgen excess, oligo\/anovulation, and polycystic appearance of the ovaries. Women with PCOS have an increased prevalence of multiple cardiovascular risk factors such as insulin resistance, hypertension, renal injury, and obesity. Unfortunately, there is a lack of effective, evidence-based pharmacotherapeutics to target these cardiometabolic complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular protection in patients with and without type 2 diabetes mellitus. Although the exact mechanisms of how SGLT2 inhibitors confer cardiovascular protection remains unclear, numerous mechanistic hypotheses for this protection include modulation of the renin-angiotensin system and\/or the sympathetic nervous system and improvement in mitochondrial function. Data from recent clinical trials and basic research show a potential role for SGLT2 inhibitors in treating obesity-associated cardiometabolic complications in PCOS. This narrative review discusses the mechanisms of the beneficial effect of SGLT2 inhibitors in cardiometabolic diseases in PCOS.<\/jats:p>","DOI":"10.3389\/fendo.2023.951099","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T05:49:51Z","timestamp":1676440191000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors"],"prefix":"10.3389","volume":"14","author":[{"given":"Jacob E.","family":"Pruett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian G.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licy L.","family":"Yanes Cardozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum Reprod"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dep399","article-title":"The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria","volume":"25","author":"March","year":"2010","journal-title":"Hum Reprod"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.9.3078","article-title":"Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern united states: a prospective study","volume":"83","author":"Knochenhauer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","first-page":"140","volume-title":"The aphorisms of Hippocrates: With a translation into Latin and English","author":"Hippocrates","year":"1822"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(15)30642-6","article-title":"Amenorrhea associated with bilateral polycystic ovaries","volume":"29","author":"Stein","year":"1935","journal-title":"Am J Obstet Gynecol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum reproduction"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0178","article-title":"Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","article-title":"Diagnostic criteria for polycystic ovary syndrome: towards a rational approach","volume-title":"Polycystic ovary syndrome","author":"Zawadski","year":"1992"},{"key":"B9","article-title":"Hirsutism in women","volume":"85","author":"Bode","year":"2012","journal-title":"Am Fam Physician"},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3121\/cmr.2.1.13","article-title":"Polycystic ovarian syndrome: diagnosis and management","volume":"2","author":"Sheehan","year":"2004","journal-title":"Clin Med Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2935","article-title":"Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the united states and Europe","volume":"102","author":"Travison","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00030.2016","article-title":"Cardiometabolic features of polycystic ovary syndrome: role of androgens","volume":"32","author":"Yanes Cardozo","year":"2017","journal-title":"Physiology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003132","article-title":"Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis","volume":"17","author":"Dapas","year":"2020","journal-title":"PLoS Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007813","article-title":"Large-Scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria","volume":"14","author":"Day","year":"2018","journal-title":"PLoS Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:104186","article-title":"Deaths: Leading causes for 2019","volume":"70","author":"Heron","year":"2021","journal-title":"Natl Vital Stat Reports: Natl Center Health Stat"},{"key":"B16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1210\/er.2015-1018","article-title":"Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome","volume":"36","author":"Dumesic","year":"2015","journal-title":"Endocr Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2430","article-title":"Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome","volume":"91","author":"Lo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/16.3.556","article-title":"Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population","volume":"16","author":"Elting","year":"2001","journal-title":"Hum Reprod"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14219","article-title":"Serum testosterone acts as a prognostic indicator in polycystic ovary syndrome-associated kidney injury","volume":"7","author":"Song","year":"2019","journal-title":"Physiol Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab509","article-title":"Cardiovascular events in polycystic ovary syndrome: Is the debate settled for good","volume":"106","author":"Romero","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-1108","article-title":"Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome","volume":"172","author":"Glintborg","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-018-0680-5","article-title":"Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome","volume":"17","author":"Glintborg","year":"2018","journal-title":"Cardiovasc diabetology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.552421","article-title":"Risk of cardiovascular and cerebrovascular events in polycystic ovarian syndrome women: a meta-analysis of cohort studies","volume":"7","author":"Zhang","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab392","article-title":"Women with polycystic ovary syndrome have an increased risk of major cardiovascular events: a population study","volume":"106","author":"Berni","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202002526RR","article-title":"Management of cardiometabolic complications in polycystic ovary syndrome: Unmet needs","volume":"35","author":"Yanes Cardozo","year":"2021","journal-title":"FASEB J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1938.122.3.765","article-title":"The renal tubular reabsorption of glucose in the normal dog","volume":"122","author":"Shannon","year":"1938","journal-title":"Am J Physiology-Legacy Content"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1976.18","article-title":"Genetic aspects of renal tubular transport: diversity and topology of carriers","volume":"9","author":"Scriver","year":"1976","journal-title":"Kidney Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1982.242.4.F406","article-title":"Heterogeneity of sodium-dependent d-glucose transport sites along the proximal tubule: evidence from vesicle studies","volume":"242","author":"Turner","year":"1982","journal-title":"Am J Physiology-Renal Physiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.49.29365","article-title":"Molecular characteristics of na+-coupled glucose transporters in adult and embryonic rat kidney","volume":"270","author":"You","year":"1995","journal-title":"J Biol Chem"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1113\/jphysiol.1995.sp020559","article-title":"Mammalian ion-coupled solute transporters","volume":"482","author":"Hediger","year":"1995","journal-title":"J Physiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J Am Soc Nephrology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/00325481.2018.1394152","article-title":"SGLT2 inhibitors: are they safe","volume":"130","author":"Filippas-Ntekouan","year":"2018","journal-title":"Postgrad Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.129825","article-title":"Inhibitor binding in the human renal low- and high-affinity na+\/glucose cotransporters","volume":"324","author":"Pajor","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)36592-4","article-title":"Structure of the human na+\/glucose cotransporter gene SGLT1","volume":"269","author":"Turk","year":"1994","journal-title":"J Biol Chem"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2337\/diaclin.28.1.5","article-title":"Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition","volume":"28","author":"White","year":"2010","journal-title":"Clin Diabetes"},{"key":"B38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab765","article-title":"SGLT2 inhibitors: the statins of the 21st century","volume":"43","author":"Braunwald","year":"2022","journal-title":"Eur Heart J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2237","article-title":"Evaluating the cardiovascular safety of new medications for type 2 diabetes: time to reassess","volume":"39","author":"Smith","year":"2016","journal-title":"Diabetes Care"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.5.1392","article-title":"Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo","volume":"54","author":"Bogacka","year":"2005","journal-title":"Diabetes"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp078167","article-title":"The rosiglitazone story\u2013lessons from an FDA advisory committee meeting","volume":"357","author":"Rosen","year":"2007","journal-title":"New Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"New Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"New Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"New Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"New Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2924","article-title":"Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data","volume":"33","author":"Blau","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"New Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"New Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1581971","article-title":"SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses","volume":"131","author":"Filippatos","year":"2019","journal-title":"Postgraduate Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13968","article-title":"Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study","volume":"90","author":"Javed","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab408","article-title":"Exenatide, dapagliflozin, or Phentermine\/Topiramate differentially affect metabolic profiles in polycystic ovary syndrome","volume":"106","author":"Elkind-Hirsch","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14495","article-title":"Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial","volume":"23","author":"Tan","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22764","article-title":"Licogliflozin, a novel SGLT1 and 2 inhibitor: body weight effects in a randomized trial in adults with overweight or obesity","volume":"28","author":"Bays","year":"2020","journal-title":"Obesity"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dei258","article-title":"The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome","volume":"20","author":"Yilmaz","year":"2005","journal-title":"Hum Reproduction"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(88)90344-5","article-title":"Androgen levels during sequential insulin euglycemic clamp studies in patients with polycystic ovary disease","volume":"31","author":"Micic","year":"1988","journal-title":"J Steroid Biochem"},{"key":"B61","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/humrep\/12.suppl_1.53","article-title":"Insulin regulation of human ovarian androgens","volume":"12","author":"Nestler","year":"1997","journal-title":"Hum Reprod"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1210\/er.2016-1067","article-title":"Dihydrotestosterone: biochemistry, physiology, and clinical implications of elevated blood levels","volume":"38","author":"Swerdloff","year":"2017","journal-title":"Endocrine Rev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.12.4420","article-title":"Effects of methyltestosterone on insulin secretion and sensitivity in women","volume":"83","author":"Diamond","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1210\/en.2007-0168","article-title":"A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome","volume":"148","author":"Manneras","year":"2007","journal-title":"Endocrinology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.genm.2010.11.013","article-title":"Cardiovascular-renal and metabolic characterization of a rat model of polycystic ovary syndrome","volume":"8","author":"Yanes","year":"2011","journal-title":"Gender Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMcp1514916","article-title":"Polycystic ovary syndrome","volume":"375","author":"McCartney","year":"2016","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-S010","article-title":"7. approaches to glycemic treatment","volume":"38","author":"Association","year":"2015","journal-title":"Diabetes Care"},{"key":"B68","doi-asserted-by":"publisher","first-page":"5150684","DOI":"10.1155\/2020\/5150684","article-title":"The effect of metformin on polycystic ovary syndrome in overweight women: a systematic review and meta-analysis of randomized controlled trials","volume":"2020","author":"Guan","year":"2020","journal-title":"Int J Endocrinol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1380269","article-title":"Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome","volume":"138","author":"Diamanti-Kandarakis","year":"1998","journal-title":"Eur J Endocrinology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3109\/07435800.2014.966385","article-title":"Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome","volume":"40","author":"Jensterle","year":"2015","journal-title":"Endocrine Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.rbmo.2019.04.017","article-title":"GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis","volume":"39","author":"Han","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-1617","article-title":"Cardiometabolic effects of chronic hyperandrogenemia in a new model of postmenopausal polycystic ovary syndrome","volume":"157","author":"Dalmasso","year":"2016","journal-title":"Endocrinology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"bnaa010","DOI":"10.1210\/endrev\/bnaa010","article-title":"Animal models to understand the etiology and pathophysiology of polycystic ovary syndrome","volume":"41","author":"Stener-Victorin","year":"2020","journal-title":"Endocrine Rev"},{"key":"B74","doi-asserted-by":"publisher","first-page":"bqac164","DOI":"10.1210\/endocr\/bqac164","article-title":"Update on animal models of polycystic ovary syndrome","volume":"163","author":"Stener-Victorin","year":"2022","journal-title":"Endocrinology"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a019028","article-title":"Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: A sign of a pre-hypertensive state","volume":"11","author":"Holte","year":"1996","journal-title":"Hum Reprod"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0527","article-title":"Higher blood pressure in normal weight women with PCOS compared to controls","volume":"10","author":"Mellembakken","year":"2021","journal-title":"Endoc Connect"},{"key":"B77","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000201791","article-title":"Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy","volume":"32","author":"Diamanti-Kandarakis","year":"2009","journal-title":"Kidney Blood Press Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2007.6.864","article-title":"Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: Case series","volume":"48","author":"Jensterle","year":"2007","journal-title":"Croat Med J"},{"key":"B79","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/clc.4960141802","article-title":"Control of blood pressure by the renin-angiotensin-aldosterone system","volume":"14","author":"Hall","year":"1991","journal-title":"Clin Cardiol"},{"key":"B80","volume-title":"Guyton and Hall textbook of medical physiology","author":"Hall","year":"2016"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1002\/cphy.c120002","article-title":"Non-classical renin-angiotensin system and renal function","volume":"2","author":"Chappell","year":"2012","journal-title":"Compr Physiol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.regpep.2012.04.001","article-title":"The Mas receptor mediates modulation of insulin signaling by angiotensin-(1\u20137)","volume":"177","author":"Mu\u00f1oz","year":"2012","journal-title":"Regul peptides"},{"key":"B83","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/jcdd6020014","article-title":"An update on the tissue renin angiotensin system and its role in physiology and pathology","volume":"6","author":"Nehme","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1999.277.3.F437","article-title":"Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney","volume":"277","author":"Miyata","year":"1999","journal-title":"Am J Physiology-Renal Physiol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.163519","article-title":"Intratubular renin-angiotensin system in hypertension","volume":"57","author":"Navar","year":"2011","journal-title":"Hypertension"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117312","article-title":"Renin and renin mRNA in proximal tubules of the rat kidney","volume":"94","author":"Chen","year":"1994","journal-title":"J Clin Invest"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116296","article-title":"Renin expression in renal proximal tubule","volume":"91","author":"Moe","year":"1993","journal-title":"J Clin Invest"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000135678.20725.54","article-title":"Enhancement of collecting duct renin in angiotensin II\u2013dependent hypertensive rats","volume":"44","author":"Prieto-Carrasquero","year":"2004","journal-title":"Hypertension"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.64.s86.12.x","article-title":"Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy","volume":"64","author":"Mezzano","year":"2003","journal-title":"Kidney Int"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000081221.36703.01","article-title":"Angiotensin I conversion to angiotensin II stimulates cortical collecting duct sodium transport","volume":"42","author":"Komlosi","year":"2003","journal-title":"Hypertension"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00368.2011","article-title":"Angiotensin II stimulates epithelial sodium channels in the cortical collecting duct of the rat kidney","volume":"302","author":"Sun","year":"2012","journal-title":"Am J Physiology-Renal Physiol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00159.x","article-title":"Ion channels and the control of blood pressure","volume":"49","author":"Baker","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"100052","DOI":"10.1016\/j.metop.2020.100052","article-title":"Renin-angiotensin system overactivation in polycystic ovary syndrome, a risk for SARS-CoV-2 infection","volume":"7","author":"Moin","year":"2020","journal-title":"Metab Open"},{"key":"B95","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4330\/wjc.v3.i3.72","article-title":"Renin and cardiovascular disease: Worn-out path, or new direction","volume":"3","author":"Alreja","year":"2011","journal-title":"World J Cardiol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1210\/en.2019-00450","article-title":"Effect of GLP-1 receptor agonists in the cardiometabolic complications in a rat model of postmenopausal PCOS","volume":"160","author":"Torres Fernandez","year":"2019","journal-title":"Endocrinology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.3390\/ijms22052576","article-title":"Impact of SGLT-2 inhibition on cardiometabolic abnormalities in a rat model of polycystic ovary syndrome","volume":"22","author":"Pruett","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055202","article-title":"Major congenital malformations after first-trimester exposure to ACE inhibitors","volume":"354","author":"Cooper","year":"2006","journal-title":"New Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0140-6736(00)03648-5","article-title":"Losartan and fetal toxic effects","volume":"357","author":"Saji","year":"2001","journal-title":"Lancet"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05426-5","article-title":"Fetal toxic effects and angiotensin-II-receptor antagonists","volume":"358","author":"Martinovic","year":"2001","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12902-020-00656-8","article-title":"Effect of sodium\u2013glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: A retrospective observational study","volume":"20","author":"Sawamura","year":"2020","journal-title":"BMC Endocrine Disord"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037418","article-title":"Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging","volume":"140","author":"Kidokoro","year":"2019","journal-title":"Circulation"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin\u2013angiotensin\u2013aldosterone system in type 2 diabetes: A prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14360","article-title":"Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume","volume":"8","author":"Masuda","year":"2020","journal-title":"Physiol Rep"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1159\/000499597","article-title":"Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus","volume":"49","author":"Woods","year":"2019","journal-title":"Am J Nephrol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165703","article-title":"Effect of sodium-glucose Co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes","volume":"11","author":"Shin","year":"2016","journal-title":"PLoS One"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12436","article-title":"Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl s rats","volume":"3","author":"Kojima","year":"2015","journal-title":"Physiol Rep"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00113.2003","article-title":"Angiotensin II-dependent increased expression of na+-glucose cotransporter in hypertension","volume":"286","author":"Bautista","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-474X.2006.00122.x","article-title":"Heart rate variability in young women with polycystic ovary syndrome","volume":"11","author":"Yildirir","year":"2006","journal-title":"Ann Noninvasive Electrocardiology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00411.2014","article-title":"Roles for the sympathetic nervous system, renal nerves, and CNS melanocortin-4 receptor in the elevated blood pressure in hyperandrogenemic female rats","volume":"308","author":"Maranon","year":"2015","journal-title":"Am J Physiology-Regulatory Integr Comp Physiol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328344db3a","article-title":"Renal denervation: A potential new treatment modality for polycystic ovary syndrome","volume":"29","author":"Schlaich","year":"2011","journal-title":"J Hypertens"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2011.04.073","article-title":"Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome","volume":"96","author":"Yildizhan","year":"2011","journal-title":"Fertil Steril"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0145-4","article-title":"Obesity, kidney dysfunction and hypertension: Mechanistic links","volume":"15","author":"Hall","year":"2019","journal-title":"Nat Rev Nephrology"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11906-019-0951-x","article-title":"Melanocortin-4 receptors and sympathetic nervous system activation in hypertension","volume":"21","author":"da Silva","year":"2019","journal-title":"Curr Hypertension Rep"},{"key":"B115","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American college of cardiology solution set oversight committee","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6824.405","article-title":"Medical research council trial of treatment of hypertension in older adults: Principal results","volume":"304","year":"1992","journal-title":"BMJ"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)00092-1","article-title":"Implications of discontinuation of doxazosin arm of ALLHAT","volume":"355","author":"Messerli","year":"2000","journal-title":"Lancet"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14279","article-title":"Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance","volume":"37","author":"Nojima","year":"2020","journal-title":"Diabetic Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12726","article-title":"Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials","volume":"9","author":"Sano","year":"2018","journal-title":"J Diabetes Invest"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor\u2013induced sympathoinhibition: a novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC: Basic to Trans Science"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1055\/a-0958-2441","article-title":"Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes","volume":"51","author":"Wu","year":"2019","journal-title":"Hormone Metab Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.yexmp.2006.09.008","article-title":"Mitochondrial dysfunction and molecular pathways of disease","volume":"83","author":"Pieczenik","year":"2007","journal-title":"Exp Mol Pathol"},{"key":"B123","first-page":"35","article-title":"Mitochondrial dysfunction and chronic disease: Treatment with natural supplements","volume":"13","author":"Nicolson","year":"2014","journal-title":"Integr Med (Encinitas)"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1279250","DOI":"10.1155\/2019\/1279250","article-title":"Approaches and methods to measure oxidative stress in clinical samples: Research applications in the cancer field","volume":"2019","author":"Katerji","year":"2019","journal-title":"Oxid Med Cell Longevity"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2016.11.010","article-title":"Mitochondrial dysfunction and oxidative stress in metabolic disorders\u2013a step towards mitochondria based therapeutic strategies","volume":"1863","author":"Bhatti","year":"2017","journal-title":"Biochim Biophys Acta Basis Dis"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1172\/JCI120849","article-title":"Mitochondrial dysfunction in pathophysiology of heart failure","volume":"128","author":"Zhou","year":"2018","journal-title":"J Clin Invest"},{"key":"B127","doi-asserted-by":"publisher","first-page":"11253","DOI":"10.3390\/ijms222011253","article-title":"The role of mitochondria in acute kidney injury and chronic kidney disease and its therapeutic potential","volume":"22","author":"Zhang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12958-019-0509-4","article-title":"Polycystic ovary syndrome and mitochondrial dysfunction","volume":"17","author":"Zhang","year":"2019","journal-title":"Reprod Biol Endocrinol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2011.04.010","article-title":"Mitochondrial DNA copy number in peripheral blood in polycystic ovary syndrome","volume":"60","author":"Lee","year":"2011","journal-title":"Metabolism"},{"key":"B130","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mito.2017.12.010","article-title":"Impact of mitochondrial DNA copy number and displacement loop alterations on polycystic ovary syndrome risk in south Indian women","volume":"44","author":"Reddy","year":"2019","journal-title":"Mitochondrion"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0553","article-title":"Prenatal androgen induced lean PCOS impairs mitochondria and mRNA profiles in oocytes","volume":"9","author":"Chappell","year":"2020","journal-title":"Endocrine connections"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.2337\/db17-1032","article-title":"Oxidative stress inhibits healthy adipose expansion through suppression of SREBF1-mediated lipogenic pathway","volume":"67","author":"Okuno","year":"2018","journal-title":"Diabetes"},{"key":"B133","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1161\/CIRCRESAHA.119.312321","article-title":"Obesity, hypertension, and cardiac dysfunction: Novel roles of immunometabolism in macrophage activation and inflammation","volume":"126","author":"Mouton","year":"2020","journal-title":"Circ Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2016.06.023","article-title":"PPAR\u03b3 as a therapeutic target to rescue mitochondrial function in neurological disease","volume":"100","author":"Corona","year":"2016","journal-title":"Free Radical Biol Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019995","article-title":"Effects of sodium-glucose linked transporter 2 inhibition with ertugliflozin on mitochondrial function, energetics, and metabolic gene expression in the presence and absence of diabetes mellitus in mice","volume":"10","author":"Croteau","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12802","article-title":"Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet","volume":"9","author":"Takagi","year":"2018","journal-title":"J Diabetes Invest"},{"key":"B138","doi-asserted-by":"publisher","first-page":"117414","DOI":"10.1016\/j.lfs.2020.117414","article-title":"Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPAR\u03b1 in vivo and in vitro","volume":"247","author":"Wei","year":"2020","journal-title":"Life Sci"},{"key":"B139","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13293-022-00455-x","article-title":"Mitochondrial function and oxidative stress in white adipose tissue in a rat model of PCOS: Effect of SGLT2 inhibition","volume":"13","author":"Pruett","year":"2022","journal-title":"Biol Sex Differ"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0002052022","article-title":"Polycystic ovary syndrome: Insights from preclinical research","volume":"3","author":"Reckelhoff","year":"2022","journal-title":"Kidney360"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.025839","article-title":"Trends, predictors, and outcomes of cardiovascular complications associated with polycystic ovary syndrome during delivery hospitalizations: A national inpatient sample analysis (2002\u20132019)","volume":"11","author":"Zahid","year":"2022","journal-title":"J Am Heart Assoc"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.951099\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T05:49:58Z","timestamp":1676440198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.951099\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":141,"alternative-id":["10.3389\/fendo.2023.951099"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.951099","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"article-number":"951099"}}